Johnson & Johnson

Johnson & Johnson is one of the largest global pharma-and-medical-devices companies — Innovative Medicine, MedTech (Ethicon, DePuy Synthes), plus a legacy consumer-health separation. The setup is a real-business compounder near all-time highs on a specific drug catalyst.

• The Imaavy approval is the specific catalyst: FDA approval of Imaavy for warm autoimmune hemolytic anemia (wAIHA) as the first treatment for the rare blood disorder is a small but incremental revenue driver, and the tape read is +3.8% into a healthcare-sector rotation — Buffett-adjacent commentary and A+ buy signals from technical services are keeping the bid on.
• The core P&L is quality-cliché quality: Q1 revenue grew 9.9% YoY to $24.1B at a 71% gross margin and 27% operating margin, Q2 EPS beat at $2.90 vs $2.84 consensus, and the sell side models FY26 EPS at ~$11.68 rising to ~$14.34 by 2028 — the pipeline supports the mid-teens EPS-growth trajectory even with the Xarelto and Stelara loss-of-exclusivity headwinds.
• The insider signal is the loud negative: CEO Joaquin Duato sold ~$32.2M on August 13 after M-Exempt exercises, EVP Taubert sold ~$3.95M on August 17, and CFO-office equivalent Forminard sold ~$4.09M on August 6 — combined ~$40M+ of officer selling into strength at 92% of the 52-week range is exactly the tell you'd want to respect.

The setup is a real-business quality name accelerating on a fresh approval with a loud insider counter-signal — the October 13 Q3 print is the referee, and the market needs continued mid-single-digit revenue growth plus reiterated FY26 EPS guide. A clean beat plus continued MedTech acceleration extends the trajectory into a trillion-dollar market-cap discussion; another cluster of Duato or Taubert selling above $275 cools the tape from the 52-week high.